The U.S. Food and Drug Administration’s rejection of Replimune’s advanced skin cancer drug has drawn scrutiny from Capitol Hill, pitting the agency’s evidentiary standards against oncologists who say the treatment works.

Health and Human Services Secretary Robert F. Kennedy Jr. told a Senate hearing Wednesday that he played no role in the FDA’s decision not to approve Replimune’s drug, attributing the determination entirely to FDA Commissioner Marty Makary. “This decision comes out of FDA, and we trust the process there,” Kennedy said. “And I’ve been told by Marty Makary that every panel that looked at that drug unanimously voted against it because it does not appear to work.” An op-ed published in The Wall Street Journal challenged that account directly, citing cancer physicians who had worked on trials of the drug and said it demonstrated clinical effectiveness.

The FDA declined to approve the Replimune agent earlier in April 2026, citing methodological concerns with the company’s submission. The agency objected to Replimune’s reliance on a single-arm study lacking a control group. That design limitation, regulators said, prevented the agency from drawing reliable conclusions about the drug’s efficacy in advanced skin cancer. In its complete response letter, the FDA indicated that Replimune must provide data from a well-controlled trial demonstrating adequate evidence of effectiveness before the application could be reconsidered.

The methodological gap matters. Single-arm trials don’t establish causation.

That standard, while rigorous, reflects the FDA’s longstanding evidentiary framework for oncology approvals. Without a randomized comparator arm, it’s difficult to determine whether observed tumor responses reflect the drug’s mechanism of action or the natural course of disease, patient selection bias, or regression to the mean. The FDA’s position is that a single-arm study, even one showing a meaningful response rate, can’t reliably differentiate drug effect from confounding. That argument has been applied consistently across multiple therapeutic areas, though its application in settings where randomized trials are logistically difficult or ethically complex has generated ongoing debate within the oncology community.

The case touches a broader tension. Oncologists treating patients with advanced skin malignancies, for whom therapeutic options are limited, often advocate for accelerated pathways that accept surrogate endpoints, particularly objective response rate and duration of response, as proxies for clinical benefit. The FDA has used accelerated approval mechanisms to allow drugs to market based on such surrogates, subject to confirmatory trial requirements. Whether Replimune’s submission met even that lower bar was the central dispute. Kennedy’s characterization that every reviewing panel voted unanimously against the drug is contested. The Wall Street Journal op-ed, citing clinicians with direct trial experience, maintained that the drug was effective. That dispute over the underlying data will likely continue as Replimune determines its next steps.

No hazard ratio data, no progression-free survival curves, no confidence intervals from Replimune’s trial were disclosed publicly in the course of Kennedy’s Senate testimony or in subsequent reporting. The absence of granular endpoint data makes independent clinical assessment difficult from publicly available information alone. What’s clear is that the FDA’s position rests on the absence of a control arm, not on a finding that the drug caused harm.

Replimune’s path forward is constrained. Designing and executing a randomized controlled trial (RCT) in advanced skin cancer with a defined comparator will require substantial time and resources. Depending on the competitive treatment landscape at time of enrollment, the company may also face challenges in recruiting patients who have access to approved alternatives. The FDA’s letter, while a rejection, stops short of closing the door permanently. It functions as a deficiency notice, not a clinical hold.

Separately, a parallel set of concerns has emerged around the financial architecture of telehealth medicine. As reported by STAT News, links between pharmaceutical manufacturers and telehealth platforms have drawn scrutiny from health policy experts and legislators over the substantial fees that telehealth companies can receive from drugmakers annually. Critics have raised questions about whether those arrangements violate federal laws prohibiting financial kickbacks intended to induce prescribing.

The concern isn’t abstract. It’s structural.

When a pharmaceutical company pays a telehealth platform a fee, and that platform’s prescribers write scripts for that company’s branded products, the relationship creates an incentive structure that may influence clinical decision-making in ways patients can’t observe. Existing federal anti-kickback statutes, administered under the Department of Health and Human Services Office of Inspector General, prohibit remuneration designed to induce or reward referrals for items or services covered by federal healthcare programs. Whether the fees flowing from manufacturers to telehealth platforms constitute prohibited remuneration under those statutes is a legal question that has not been fully adjudicated. The HHS Office of Inspector General publishes safe harbor regulations that delineate permissible financial arrangements, but the telehealth-pharma partnership model presents novel fact patterns that don’t map cleanly onto existing safe harbors.

The coupon mechanism adds a secondary layer of complexity. Drugmakers have historically used discount coupons to reduce patients’ out-of-pocket costs for branded medications, a practice that has itself attracted regulatory scrutiny because coupons can insulate patients from the true cost of high-priced drugs, thereby reducing price sensitivity and undermining payer formulary management. The emerging concern in the telehealth context is that coupons can now reduce not only the cost of the drug itself but also the cost of the clinical consultation required to obtain a prescription for it. A drug-specific telehealth visit underwritten by the manufacturer functionally creates an end-to-end subsidized pathway to a branded prescription. That pathway bypasses the patient’s primary care relationship, may discourage consideration of generic or lower-cost therapeutic alternatives, and raises questions about care coordination.

Critics have also pointed to the risk of overprescribing. Branded medications recommended through manufacturer-affiliated telehealth channels may be appropriate for some patients and not for others. Without access to a patient’s full medical history, existing medication list, comorbidities, and prior treatment record, a telehealth prescriber evaluating a patient for a specific drug may lack the clinical context necessary to identify contraindications or preferable alternatives. The concern is amplified when the commercial incentives of the platform are aligned with a single product.

For physicians practicing in Hawaii, where patient populations include substantial Native Hawaiian and Pacific Islander communities with documented disparities in access to primary care and specialty services, the telehealth-pharma relationship warrants particular attention. Telehealth has expanded access for patients in rural and underserved communities. That’s not in dispute. But access to a telehealth visit that functions as a delivery mechanism for a branded prescription isn’t the same as access to coordinated, longitudinal care. The distinction matters clinically, and it matters more for patients who don’t have a primary care physician to catch downstream problems.

Legislative scrutiny is active. Health policy experts and legislators cited in reporting on the issue have raised concerns specifically about the scale of fees pharmaceutical companies pay to telehealth partners, suggesting that the dollar amounts involved are substantial enough to create meaningful prescribing pressure. The federal anti-kickback framework was designed precisely to address situations in which financial relationships corrupt clinical judgment. Whether enforcement agencies will pursue investigations or whether Congress will move to clarify the statutory framework for telehealth-pharma arrangements remains an open regulatory question as of April 2026.

The Centers for Medicare and Medicaid Services has expanded telehealth coverage substantially following policy changes implemented during and after the COVID-19 public health emergency. That expansion has created a larger reimbursement base within which telehealth-pharma partnerships can operate, increasing both the commercial opportunity and the potential scale of harm if those partnerships distort prescribing in covered populations.

For oncologists and other specialists, both stories reflect a common thread: the integrity of the clinical decision-making environment. Whether the question is an FDA approval standard that demands controlled trial data before endorsing a cancer drug, or a financial relationship between a telehealth platform and a manufacturer that may influence which products a prescriber reaches for, the underlying issue is whether the system reliably directs patients toward treatments that are effective and appropriate rather than treatments that are commercially advantageous. In the Replimune case, the FDA’s demand for a controlled trial is a structural safeguard. It’s not comfortable for companies with drugs their clinicians believe work. But it exists because history demonstrates that uncontrolled data misleads, sometimes catastrophically. The telehealth-pharma fee controversy reflects a different failure mode: not inadequate evidence, but financial architecture that may corrupt the use of evidence that already exists.

Kennedy’s testimony on Wednesday, and the Wall Street Journal response from treating oncologists, make clear that the Replimune decision will not be resolved quietly. The company has not publicly announced a timeline for designing a confirmatory RCT.